Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.XenaCare launches new dietary supplement
The SunPill is a proprietary combination of ingredients with powerful antioxidant properties that help the body’s own natural defense when it comes to exposure to the sun. XenaCare
The SunPill is a proprietary combination of ingredients with powerful antioxidant properties that help the body’s own natural defense when it comes to exposure to the sun. XenaCare
View 2 will enroll approximately 1,200 patients in up to 200 centers in Europe, Asia Pacific, Japan and Latin America. The first Phase III trial, View 1, began
In accordance with the existing collaboration agreement, LFB will be providing additional funding to support GTC’s work in the recombinant human alpha-1 antitrypsin program for 2008. In addition
The interim open label extension (OLE) analyses show that 100% of the patients who were responders for the control of plasma uric acid (PUA) in Phase III and
The preliminary analysis showed that Genz-112638 produced promising efficacy results at six months and that these results continued to improve through one year of treatment. At six months,
Under terms of the agreement Regenesis will provide its specialized sales force to market Advanced BioHealing’s product Dermagraft within the Veteran’s Administration (VA), Department of Defense (DOD), and
The data showed that Intuniv demonstrated significant efficacy in reducing attention deficit hyperactivity disorder (ADHD) symptoms for patients taking the medication when compared to patients taking placebo at
Under the terms of the agreement, Quest will receive $50,000 in cash and 1.35 million common shares of Toba Industries. In addition, Quest will also receive $200,000 in
Approval by the notified body for a CE Mark would allow CardioPass to be marketed and sold in all EU countries as well as other countries worldwide that
The randomized, parallel, double-blind, placebo-controlled, dose regimen-finding study will evaluate the safety and efficacy of two dosing regimens administered to approximately 216 patients with active, seropositive rheumatoid arthritis